ALPHA.PA
Pharnext SA [ALPHA.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALPHA.PA Stock Summary
In the News
ALPHA.PA Financial details
Company Rating
Neutral
Market Cap
42.29K
Income
-67.73M
Revenue
1.23M
Book val./share
-175731615.12
Cash/share
232416.95
Dividend
-
Dividend %
-
Employees
23
Optionable
No
Shortable
Yes
Earnings
20 Apr 2024
P/E
0
Forward P/E
-
PEG
-
P/S
311.6
P/B
-
P/C
0
P/FCF
-0.01
Quick Ratio
0.03
Current Ratio
0.3
Debt / Equity
-0.79
LT Debt / Equity
-0.77
-
-
EPS (TTM)
1287675.07B
EPS next Y
-
EPS next Q
-
EPS this Y
-99.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-75.17%
Revenue last 5Y
-84.78%
Revenue Q/Q
-85.81%
EPS Q/Q
266346600.99%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-491%
ROE
152%
ROC
2.09%
Gross Margin
100%
Oper. Margin
-4985304%
Profit Margin
-6906213%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.175-8.04E7
52W High
-
52W Low
-
RSI
28
Rel Volume
3.85
Avg Volume
18.53K
Volume
71.36K
Perf Week
-7.83%
Perf Month
-57.06%
Perf Quarter
-99.97%
Perf Half Y
-99.98%
-
-
-
-
Beta
-315.381
-
-
Volatility
0.01%, 0.06%
Prev Close
14.76%
Price
0.1718
Change
12.29%
ALPHA.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.83K | 82.88 | 10.27 | 27.88 | 0 | |
| Net income per share | -8.82K | -7.64K | -5.56K | -10.07K | -8.32 | |
| Operating cash flow per share | -6.59K | -7.53K | -4.56K | -8.16K | -5.91 | |
| Free cash flow per share | -6.75K | -7.56K | -4.57K | -8.19K | -5.92 | |
| Cash per share | 10.25K | 5.33K | 2.86K | 2.62K | 0.13 | |
| Book value per share | -10.9K | -2.38K | -3.23K | -5.87K | -7.07 | |
| Tangible book value per share | -10.92K | -2.38K | -3.23K | -5.87K | -7.07 | |
| Share holders equity per share | -10.9K | -2.38K | -3.23K | -5.87K | -7.07 | |
| Interest debt per share | 20.45K | 8.82K | 6.04K | 8.28K | 5 | |
| Market cap | 63420000000B | 43157498475B | 32010000000B | 1368450076.03B | 62406571.5B | |
| Enterprise value | 63420000000.02B | 43157498475.01B | 32010000000.01B | 1368450076.04B | 62406571.52B | |
| P/E ratio | 2975.14B | 1851.52B | 1484.41B | -44.69B | -1.62B | |
| Price to sales ratio | 9286.91B | 170736.19B | 803665.58B | 16140.24B | 111839.73B | |
| POCF ratio | 3985.91B | 1877.94B | 1808.05B | -55.13B | -2.28B | |
| PFCF ratio | 3891.49B | 1872.09B | 1804.82B | -54.96B | -2.28B | |
| P/B Ratio | 2407.25B | 5956.11B | 2556.92B | -76.64B | -1.91B | |
| PTB ratio | 2407.25B | 5956.11B | 2556.92B | -76.64B | -1.91B | |
| EV to sales | 9286.91B | 170736.19B | 803665.58B | 16140.24B | 111839.73B | |
| Enterprise value over EBITDA | 3559.53B | 1889.13B | 1575.48B | -54.45B | -2.12B | |
| EV to operating cash flow | 3985.91B | 1877.94B | 1808.05B | -55.13B | -2.28B | |
| EV to free cash flow | 3891.49B | 1872.09B | 1804.82B | -54.96B | -2.28B | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | -1.76 | -3.28 | -1.7 | -1.24 | -0.68 | |
| Debt to assets | 1.5 | 1.03 | 1 | 1.35 | 2.85 | |
| Net debt to EBITDA | -1.38 | -0.43 | -0.5 | -0.57 | -0.75 | |
| Current ratio | 3.17 | 2.17 | 1.31 | 0.81 | 0.3 | |
| Interest coverage | -5.97 | -7.45 | -9.83 | -8.81 | -39.1 | |
| Income quality | 0.75 | 0.99 | 0.82 | 0.81 | 0.71 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.64 | -0.51 | 0 | 0 | |
| Sales general and administrative to revenue | 0.63 | 19.74 | 152.49 | 55.39 | 13.28K | |
| Research and developement to revenue | 2.59 | 59.03 | 317.95 | 225.58 | 36.86K | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.06 | -0.28 | -0.8 | -0.91 | -63.61 | |
| Capex to depreciation | 3.14 | -0.14 | -0.02 | -0.06 | -0.05 | |
| Stock based compensation to revenue | -0.06 | -0.27 | 4.95 | -0.02 | -128.75 | |
| Graham number | 46.53K | 20.21K | 20.09K | 36.47K | 36.38 | |
| ROIC | -0.73 | -1.23 | -2.15 | -5.14 | 2.88 | |
| Return on tangible assets | -0.69 | -1.01 | -1.01 | -1.86 | -4.89 | |
| Graham Net | -12.85K | -3.5K | -4.85K | -7.35K | -8.18 | |
| Working capital | 20.3M | 11.69M | 4.88M | -3.76M | -14.77M | |
| Tangible asset value | -26.38M | -7.26M | -12.53M | -17.86M | -32.7M | |
| Net current asset value | -27.68M | -8.77M | -13.37M | -18.76M | -34.15M | |
| Invested capital | -1.76 | -3.28 | -1.7 | -1.24 | -0.68 | |
| Average receivables | 5.71M | 5.37M | 4.9M | 5.25M | 4.1M | |
| Average payables | 5.38M | 5.31M | 6.07M | 6.98M | 5.81M | |
| Average inventory | -5.71M | -3.05M | 0 | 0 | 0 | |
| Days sales outstanding | 326.45 | 6.7K | 47.34K | 22.96K | 1.87M | |
| Days payables outstanding | 3.76K | 2.24K | 9.48K | -579.86 | -984.23 | |
| Days of inventory on hand | -3.32K | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.12 | 0.05 | 0.01 | 0.02 | 0 | |
| Payables turnover | 0.1 | 0.16 | 0.04 | -0.63 | -0.37 | |
| Inventory turnover | -0.11 | 0 | 0 | 0 | 0 | |
| ROE | 0.81 | 3.22 | 1.72 | 1.71 | 1.18 | |
| Capex per share | -159.79 | -23.56 | -8.16 | -25.32 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 1.44 | 859.11K | |
| Net income per share | 0 | 0 | 0 | -26.27 | -69.97M | |
| Operating cash flow per share | 0 | 0 | 0 | -19.83 | -56M | |
| Free cash flow per share | 0 | 0 | 0 | -19.88 | -56.1M | |
| Cash per share | 0 | 0 | 0 | 0.81 | 232.42K | |
| Book value per share | 0 | 0 | 0 | -44.42 | -175.73M | |
| Tangible book value per share | 0 | 0 | 0 | -44.42 | -175.73M | |
| Share holders equity per share | 0 | 0 | 0 | -44.42 | -175.73M | |
| Interest debt per share | 0 | 0 | 0 | 30.48 | 146.77M | |
| Market cap | 0 | 0 | 0 | 9936324B | 274.99K | |
| Enterprise value | 16.26M | 14.24M | 19.66M | 9936324.02B | 25.2M | |
| P/E ratio | 0 | 0 | 0 | -128.46M | -0.01 | |
| Price to sales ratio | 0 | 0 | 0 | 9.4B | 1.83 | |
| POCF ratio | 0 | 0 | 0 | -680.72M | -0.03 | |
| PFCF ratio | 0 | 0 | 0 | -679.17M | -0.03 | |
| P/B Ratio | 0 | 0 | 0 | -303.89M | -0.01 | |
| PTB ratio | 0 | 0 | 0 | -303.89M | -0.01 | |
| EV to sales | 266.55 | 598.18 | 35.24K | 9.4B | 167.99 | |
| Enterprise value over EBITDA | -1.26 | -1.16 | -1.39 | -651.18M | -2.05 | |
| EV to operating cash flow | -1.05 | -1.52 | -1.54 | -680.72M | -2.58 | |
| EV to free cash flow | -1.05 | -1.52 | -1.54 | -679.17M | -2.57 | |
| Earnings yield | 0 | 0 | 0 | 0 | -44.42 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | -35.62 | |
| Debt to equity | -1.55 | -1.24 | -0.86 | -0.68 | -0.79 | |
| Debt to assets | 1.2 | 1.35 | 1.88 | 2.85 | 4.83 | |
| Net debt to EBITDA | -1.26 | -1.16 | -1.39 | -1.45 | -2.02 | |
| Current ratio | 1.05 | 0.81 | 0.44 | 0.3 | 0.37 | |
| Interest coverage | -5.74 | -19.16 | -21.01 | -191.94 | -9.2 | |
| Income quality | 1.14 | 0.55 | 0.67 | 0.75 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.85 | -0.53 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 38.34 | 99.09 | 5.2K | 4.27 | 10.41 | |
| Research and developement to revenue | 162.23 | 387.9 | 18.64K | 9.62 | 66.61 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.79 | -1.2 | -3.8 | -0.03 | -0.12 | |
| Capex to depreciation | -0.13 | -0.03 | -0.01 | -0.09 | -1.08 | |
| Stock based compensation to revenue | 1.26 | -3.31 | 199.2 | 0.04 | 0.62 | |
| Graham number | 0 | 0 | 0 | 162.05 | 525.98M | |
| ROIC | -1.31 | -2.62 | 3.98 | 1.5 | 2.09 | |
| Return on tangible assets | -0.7 | -1.04 | -1.72 | -2.46 | -2.43 | |
| Graham Net | 0 | 0 | 0 | -51.37 | -193.34M | |
| Working capital | 809.26K | -3.76M | -13.68M | -14.77M | -6.89M | |
| Tangible asset value | -15.08M | -17.86M | -24.39M | -32.7M | -30.68M | |
| Net current asset value | -16.44M | -18.76M | -24.82M | -34.15M | -31.73M | |
| Invested capital | -1.55 | -1.24 | -0.86 | -0.68 | -0.79 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 9.77K | 20.17K | 1.21M | 243.91 | 1.53K | |
| Days payables outstanding | -281.63 | -332.21 | -566.73 | 1.49K | -1.09K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.01 | 0 | 0 | 0.37 | 0.06 | |
| Payables turnover | -0.32 | -0.27 | -0.16 | 0.06 | -0.08 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.9 | 0.96 | 0.78 | 0.59 | 0.4 | |
| Capex per share | 0 | 0 | 0 | -0.05 | -100.82K |
ALPHA.PA Frequently Asked Questions
What is Pharnext SA stock symbol ?
Pharnext SA is a FR stock and trading under the symbol ALPHA.PA
What is Pharnext SA stock quote today ?
Pharnext SA stock price is $0.1718 today.
Is Pharnext SA stock public?
Yes, Pharnext SA is a publicly traded company.
Company Profile
- Volume Average 18.53K
- Market Capitalization 42.29K
- Employee 23
- CEO Mr. Hugo Brugiere M.Sc.
- Headquarters Issy-les-Moulineaux,FR
- IPO Date 2016-07-18
-
Website
https://www.pharnext.com 
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
